Growth and Safety Clinical Trial on a New Infant Formula.
Launched by NARA ORGANICS · Dec 11, 2020
Trial Information
Current as of August 31, 2025
Completed
Keywords
ClinConnect Summary
A 16-weeks length, randomized, controlled, double-blind, parallel study designed to evaluate growth and tolerance of healthy infants fed milk-based infant formula. The study has been designed in accordance with Good Clinical Practice guidelines and the requirements of the Code of Federal Regulations 21 CFR 106.96
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy gestational term (≥ 37 wks; ≤ 41 wks and 6 days).
- • Birth weight of ≥ 2,500 g and ≤ 4,500 g.
- • Postnatal age ≤ 14 days.
- • Singleton.
- • Designated as healthy, that is no recognized diseases.
- • Weight, length, weight-for-length, and head circumference within ≥ 5th and ≤ 95th percentile for age-sex according to World Health Organization (WHO) growth standards (birth to 24 months).
- • Exclusive feeding and tolerating cow milk formula at time of enrollment.
- • Parent(s) or legal guardians are willing and able to feed the assigned formula as sole source of nutrition.
- • Parent(s) or legal guardians are willing and able to participate in anthropometric procedures.
- • Parent(s) or legal guardians have voluntarily signed and dated required participation forms, such as the ICF approved by an IRB.
- Exclusion Criteria:
- • An infant from a multiple birth, such as twin, triplet, or the like.
- • Personal or immediate family history of cow-milk protein allergy or intolerance.
- • Currently on any medication to treat growth failure or that may significantly impact growth.
- • Evidence of any anatomic and/or physiologic condition that would interfere with normal growth, development, or feeding, such as genetic, neurological, gastrointestinal, cardiac, pulmonary, hepatic, or renal.
- • A maternal history with known adverse effects on the fetus and/or the newborn infant, such as positive HIV, insulin-dependent diabetes, opioid exposure during pregnancy.
- • Enrolled in another clinical trial involving a drug, nutrition supplement, device, or intervention.
About Nara Organics
Nara Organics is a pioneering clinical trial sponsor dedicated to advancing innovative solutions in health and wellness through rigorous scientific research and development. With a focus on organic and natural products, Nara Organics leverages cutting-edge methodologies to evaluate the efficacy and safety of its offerings. Committed to ethical standards and regulatory compliance, the organization collaborates with leading researchers and institutions to ensure robust clinical trial design and execution. Nara Organics aims to enhance patient outcomes and contribute to the growing field of organic health solutions, ultimately promoting a healthier and more sustainable future.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cary, North Carolina, United States
Patients applied
Trial Officials
Amanda Fingarson, DO
Study Director
Paidion Research, Inc.
Tiffany Petty, MD
Principal Investigator
Telehub Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials